Compare Las Vegas Sands Corp. (LVS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs State Street SPDR S&P Biotech ETF — how do they compare? Las Vegas Sands Corp. trades at $36.17 (market cap $23.38B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Las Vegas Sands Corp. is far larger — about 2.3× State Street SPDR S&P Biotech ETF's market cap, and Las Vegas Sands Corp. pays a 3.32% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Las Vegas Sands Corp. for 72 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| LVS | XBI | |
|---|---|---|
Market Cap | $23.38B | $10.11B |
Volume | 6,994,661 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $69.49 | $169.55 |
52-Week Low | $35.81 | $104.99 |
Typical Hold Time | 72 Days | 38 Days |
Enterprise Value | $35.27B | — |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $36.10, up 0.81% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with $13.02B revenue, 12.59% net margin, and positive cash flow of $191M in 2025. Recent news highlights Sands China's community initiatives and operational milestones, while analyst consensus remains strongly bullish with a $59.78 price target.
LVS presents a compelling value opportunity with attractive valuation multiples (P/E 13.99, EV/EBITDA 7.64) and robust profitability (ROE 134.29%). However, high debt levels and recent Q2 2026 earnings miss pose risks. The significant upside to analyst targets suggests potential for substantial returns if operational execution improves.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
